logo

For the Inventor, By the Inventor

Fontenay sous Bois, France

Daniel Humbert

This inventor holds 25 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Roussel Uclaf, Hoechst Marion Roussel, Other. Active years: 1976-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Humbert. Retrieved from https://idiyas.com/inventor/daniel-humbert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 100.0

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 159(Granted Patents)


Location History:

  • Paris, FR (1976 - 1978)
  • Fontenay-sous-Bois, FR (1978 - 1998)
  • Fonenay Sous Bois, FR (1998 - 2001)

Company Filing History:

goldMedal22 out of 854 
 
Roussel Uclaf
 patents
silverMedal1 out of 236 
 
Hoechst Marion Roussel
 patents
bronzeMedal2 out of 834,453 
Other
 patents

Years Active: 1976-2001

Loading Chart...
Areas of Expertise:
Cephalosporins
Anxiolytic Compounds
Benzodioxin Derivatives
Thiazole Derivatives
Pyridine Derivatives
Pharmaceutical Formulations
4(2-Indolyl)2-Amino-Pentanedioic Acids
Dioxo-Benzodiazepines
Azaspirodecane Compounds
Isoxazoloquinoline Derivatives
Antihypertensive Indol-2-Ones
Hypolipemiant Composition
25 patents (USPTO):Explore Patents
1. 6313305 - Cephalosporins (2001-11-06),
2. 5883248 - Cephalosporins (1999-03-16),
3. 5763617 - Cephalosporins (1998-06-09),
4. 5728828 - Cephalosporins (1998-03-17),
5. 5712266 - Cephalosporins (1998-01-27),
6. 5621095 - Cephalosporins (1997-04-15),
7. 5538963 - Cephalosporins (1996-07-23),
8. 5455238 - Cephalosporins (1995-10-03),
9. 5378697 - Cephalosporins (1995-01-03),
10. 5064853 - 4(2-indolyl)2-amino-pentanedioic acids and cholecyostokinin use thereof (1991-11-12),
11. 4988692 - 2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepines (1991-01-29),
12. 4855302 - Certain azaspirodecane compounds and a method of inducing an anxiolytic (1989-08-08),
13. 4591589 - 2-aryl pyrazolo[4,3-c]cinnolin-3-ones (1986-05-27),
14. 4588731 - Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of (1986-05-13),
15. 4450167 - 3-Quinoline carboxamides having anxiolytic activity (1984-05-22),

Title: Daniel Humbert: A Pioneer in Cephalosporin Innovations

Introduction: Daniel Humbert, based in Fontenay sous Bois, France, is a prominent inventor holding an impressive total of 25 patents. His significant contributions to the field of pharmaceuticals, particularly in cephalosporins, highlight his dedication to innovation and advancement in medicinal chemistry.

Latest Patents: Among his recent patents, Daniel Humbert has developed a notable compound involving cephalosporins. This compound is defined by its unique formula, which includes novel intermediates where the substituents are elaborated in the specification. His work in this area represents a significant advancement in antibiotic development.

Career Highlights: Throughout his career, Daniel Humbert has worked with reputable companies, most notably Roussel Uclaf. His expertise and research have led to groundbreaking developments in pharmaceutical formulations and therapeutic applications, establishing him as a key figure in the industry.

Collaborations: In his journey, Daniel has collaborated with esteemed colleagues such as Jean-Francois Chantot and Solange Gouin d'Ambrieres. These partnerships have been instrumental in advancing his research and expanding the impact of his innovations in the pharmaceutical field.

Conclusion: Daniel Humbert's dedication to the development of cephalosporins and his extensive patent portfolio underline his important role in the pharmaceutical industry. His ongoing work continues to influence drug development, contributing to better healthcare solutions worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…